Programmed Death (PD)-1 Non-Small Cell Lung Cancer Global Market Report 2025

Description

Programmed death-1 (PD-1) non-small cell lung cancer (NSCLC) is a type of lung cancer in which the tumor avoids immune system detection by utilizing the PD-1 pathway, an important immune checkpoint. PD-1 is a receptor found on T cells that, when bound by its ligands (PD-L1 or PD-L2), dampens immune responses to protect tissues from damage. In NSCLC, tumors frequently overexpress PD-L1, allowing them to evade the immune system and promote cancer growth.

The main categories in the programmed death (PD)-1 non-small cell lung cancer market include monotherapy and combination therapy. Monotherapy involves treating the disease with a single drug, without combining it with other treatments. It is applied across various therapy lines, including first-line, second-line, and later stages, and is used by diverse end users such as hospitals, specialized cancer centers, academic and research institutions, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The programmed death (PD)-1 non-small cell lung cancer market research report is one of a series of new reports from The Business Research Company that provides programmed death (PD)-1 non-small cell lung cancer market statistics, including programmed death (PD)-1 non-small cell lung cancer industry global market size, regional shares, competitors with a programmed death (PD)-1 non-small cell lung cancer market share, detailed programmed death (PD)-1 non-small cell lung cancer market segments, market trends and opportunities, and any further data you may need to thrive in the programmed death (PD)-1 non-small cell lung cancer industry. This programmed death (PD)-1 non-small cell lung cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The programmed death (PD)-1 non-small cell lung cancer market size has grown strongly in recent years. It will grow from $25.23 billion in 2024 to $27.50 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth during the historical period can be attributed to the rising prevalence of non-small cell lung cancer, increased adoption of immunotherapy in developed countries, greater awareness of cancer screening, more approvals for monoclonal antibodies, and higher healthcare spending.

The programmed death (PD)-1 non-small cell lung cancer market size is expected to see strong growth in the next few years. It will grow to $38.26 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The projected growth in the forecast period can be attributed to increasing investments in cancer-specific infrastructure, expanding patient access to biologics in emerging markets, a growing global geriatric population, enhanced reimbursement support for immunotherapies, and rising clinical success rates of PD-1 inhibitors. Key trends expected during this period include technological advancements in biomarker testing, progress in combination immunotherapy protocols, investments in personalized treatment strategies, ongoing research and development of novel PD-1 inhibitors, and innovations in immune checkpoint blockade mechanisms.

The growing adoption of personalized treatments is expected to drive growth in the programmed death (PD)-1 non-small cell lung cancer market. Personalized treatments involve medical approaches customized to an individual's genetic makeup, lifestyle, and specific disease traits to achieve more targeted and effective results. The increased demand for personalized therapies is fueled by the wider availability of genomic profiling and biomarker testing, which help identify particular mutations and biological markers, enabling clinicians to select treatments likely to be more effective for each patient. Personalized treatments assist programmed death (PD)-1 non-small cell lung cancer (NSCLC) care by tailoring therapies according to a patient's genetic profile, tumor features, and immune response. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based non-profit organization, reported that the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023, compared to six in 2022. Thus, the increasing use of personalized treatments is contributing to the expansion of the PD-1 non-small cell lung cancer market.

Key companies in the programmed death (PD)-1 non-small cell lung cancer market are conducting clinical trials on innovative therapies, such as monotherapy, to enhance patient outcomes. Monotherapy refers to a treatment strategy that employs a single drug or therapy to address a disease or condition. For instance, in March 2025, Akeso, Inc., a China-based biopharmaceutical firm, announced positive Phase III HARMONi-2 trial results evaluating Ivonescimab (AK112) combined with chemotherapy as a first-line treatment for advanced non-small cell lung cancer (NSCLC). The trial achieved its primary endpoint by significantly prolonging progression-free survival compared to pembrolizumab, showcasing the therapeutic potential of this dual-targeted bispecific antibody.

In February 2025, BioNTech SE, a Germany-based biotechnology company, acquired Biotheus Inc. for an undisclosed sum. This acquisition provided BioNTech access to Biotheus's lead candidate, PM8002, a bispecific antibody targeting PD-L1 and vascular endothelial growth factor (VEGF)-A, which is in late-stage clinical trials for non-small cell lung cancer and other solid tumors. Biotheus Inc. is a China-based company specializing in the development of multispecific biologics and immuno-oncology therapies for cancer treatment, including PD-1 therapies for NSCLC.

Major players in the programmed death (pd)-1 non-small cell lung cancer market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., MacroGenics Inc., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., and Shanghai Henlius Biotech Inc.

North America was the largest region in the programmed death (PD)-1 non-small cell lung cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in programmed death-1 (PD-1) non-small cell lung cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the programmed death-1 (PD-1) non-small cell lung cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The programmed death-1 (PD-1) non-small cell lung cancer market consists of revenues earned by entities by providing services such as clinical oncology services for immunotherapy administration, companion diagnostic testing, and comprehensive patient support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The programmed death-1 (PD-1) non-small cell lung cancer market also includes sales of pembrolizumab (Keytruda), nivolumab (Opdivo), and cemiplimab (Libtayo). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Programmed Death (PD)-1 Non-Small Cell Lung Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on programmed death (pd)-1 non-small cell lung cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for programmed death (pd)-1 non-small cell lung cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The programmed death (pd)-1 non-small cell lung cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Type: Monotherapy; Combination Therapy
2) By Line of Therapy: First-line Treatment; Second-line And Beyond
3) By End User: Hospitals; Specialty Cancer Centers; Academic And Research Institutes; Other End Users
Subsegments:
1) By Monotherapy: Pembrolizumab (Keytruda); Nivolumab (Opdivo); Cemiplimab (Libtayo); Toripalimab; Tislelizumab; Camrelizumab; Dostarlimab; Other Monotherapy Drug Types
2) By Combination Therapy: Programmed Death (PD)-1 Inhibitor And Chemotherapy; Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor; Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor; Programmed Death (PD)-1 Inhibitor And Targeted Therapy; Programmed Death (PD)-1 Inhibitor And Radiation Therapy; Triple Combination Therapy; Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine; Other Combination Drug Types
Companies Mentioned: F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; AbbVie Inc.; Sanofi S.A.; Novartis AG; GlaxoSmithKline plc; Regeneron Pharmaceuticals Inc.; Incyte Corporation; Ono Pharmaceutical Co. Ltd.; BeiGene Ltd.; BioNTech SE; Shanghai Junshi Biosciences Co. Ltd.; MacroGenics Inc.; Akeso Inc.; Arcus Biosciences Inc.; Shandong Boan Biotechnology Co. Ltd.; CStone Pharmaceuticals; iTeos Therapeutics Inc.; Summit Therapeutics Inc.; Shanghai Henlius Biotech Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r37117

1. Executive Summary

2. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Characteristics

3. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Trends And Strategies

4. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Growth Analysis And Strategic Analysis Framework

5.1. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Growth Rate Analysis
5.4. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Total Addressable Market (TAM)

6. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Segmentation

6.1. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monotherapy
Combination Therapy
6.2. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
First-line Treatment
Second-line And Beyond
6.3. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Cancer Centers
Academic And Research Institutes
Other End Users
6.4. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Sub-Segmentation Of Monotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pembrolizumab (Keytruda)
Nivolumab (Opdivo)
Cemiplimab (Libtayo)
Toripalimab
Tislelizumab
Camrelizumab
Dostarlimab
Other Monotherapy Drug Types
6.5. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Sub-Segmentation Of Combination Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Programmed Death (PD)-1 Inhibitor And Chemotherapy
Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor
Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor
Programmed Death (PD)-1 Inhibitor And Targeted Therapy
Programmed Death (PD)-1 Inhibitor And Radiation Therapy
Triple Combination Therapy
Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine
Other Combination Drug Types

7. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Regional And Country Analysis

7.1. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

8.1. Asia-Pacific Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

9.1. China Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
9.2. China Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

10.1. India Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

11.1. Japan Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
11.2. Japan Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

12.1. Australia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

13.1. Indonesia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

14.1. South Korea Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
14.2. South Korea Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

15.1. Western Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
15.2. Western Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

16.1. UK Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

17.1. Germany Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

18.1. France Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

19.1. Italy Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

20.1. Spain Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

21.1. Eastern Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
21.2. Eastern Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

22.1. Russia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

23.1. North America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
23.2. North America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

24.1. USA Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
24.2. USA Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

25.1. Canada Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
25.2. Canada Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

26.1. South America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
26.2. South America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

27.1. Brazil Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

28.1. Middle East Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
28.2. Middle East Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

29.1. Africa Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
29.2. Africa Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Competitive Landscape And Company Profiles

30.1. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Competitive Landscape
30.2. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Other Major And Innovative Companies

31.1. GlaxoSmithKline plc
31.2. Regeneron Pharmaceuticals Inc.
31.3. Incyte Corporation
31.4. Ono Pharmaceutical Co. Ltd.
31.5. BeiGene Ltd.
31.6. BioNTech SE
31.7. Shanghai Junshi Biosciences Co. Ltd.
31.8. MacroGenics Inc.
31.9. Akeso Inc.
31.10. Arcus Biosciences Inc.
31.11. Shandong Boan Biotechnology Co. Ltd.
31.12. CStone Pharmaceuticals
31.13. iTeos Therapeutics Inc.
31.14. Summit Therapeutics Inc.
31.15. Shanghai Henlius Biotech Inc.

32. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

34. Recent Developments In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

35. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market High Potential Countries, Segments and Strategies

35.1 Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market In 2029 - Countries Offering Most New Opportunities
35.2 Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market In 2029 - Segments Offering Most New Opportunities
35.3 Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer